Paraplatin®
Carboplatin is a platinum-based chemotherapy agent used to treat ovarian, lung, head and neck, and other cancers. It has a similar mechanism to cisplatin but with an improved toxicity profile.
| Dosage Form | IV Injectable (Solution) |
| Strength | 10 mg/mL; 50 mg, 150 mg, 450 mg, 600 mg vials |
| Storage | Store at 25°C. Protect from light. Discard 8 hours after dilution. |
| Category | Oncology |
| Availability | Available for Transfer |
Advanced ovarian carcinoma (initial and secondary treatment); NSCLC; head and neck cancers; testicular cancer.
Produces inter- and intra-strand DNA crosslinks, primarily at the N7 position of guanine, inhibiting DNA synthesis and function.
Each Burrard Pharmaceuticals technology transfer package for Carboplatin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.